IL116400A0 - Therapeutic use of mono and dicarboxylic acid amides with aminoalcohols or aminoethers in the manufacture of a medicament selectively active on the cannabinoid peripheral receptor - Google Patents
Therapeutic use of mono and dicarboxylic acid amides with aminoalcohols or aminoethers in the manufacture of a medicament selectively active on the cannabinoid peripheral receptorInfo
- Publication number
- IL116400A0 IL116400A0 IL11640095A IL11640095A IL116400A0 IL 116400 A0 IL116400 A0 IL 116400A0 IL 11640095 A IL11640095 A IL 11640095A IL 11640095 A IL11640095 A IL 11640095A IL 116400 A0 IL116400 A0 IL 116400A0
- Authority
- IL
- Israel
- Prior art keywords
- aminoethers
- aminoalcohols
- mono
- manufacture
- dicarboxylic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI942512A IT1271266B (it) | 1994-12-14 | 1994-12-14 | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
Publications (1)
Publication Number | Publication Date |
---|---|
IL116400A0 true IL116400A0 (en) | 1996-03-31 |
Family
ID=11369989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11640095A IL116400A0 (en) | 1994-12-14 | 1995-12-14 | Therapeutic use of mono and dicarboxylic acid amides with aminoalcohols or aminoethers in the manufacture of a medicament selectively active on the cannabinoid peripheral receptor |
Country Status (8)
Country | Link |
---|---|
US (1) | US5990170A (xx) |
EP (1) | EP0799033A1 (xx) |
JP (1) | JP4216330B2 (xx) |
AU (1) | AU4344296A (xx) |
CA (1) | CA2207850C (xx) |
IL (1) | IL116400A0 (xx) |
IT (1) | IT1271266B (xx) |
WO (1) | WO1996018391A2 (xx) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19706903A1 (de) * | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
CA2330681C (en) * | 1998-05-29 | 2008-08-26 | Andrea Giuffrida | Control of pain with endogenous cannabinoids |
IT1302264B1 (it) * | 1998-09-24 | 2000-09-05 | Innovet Italia Srl | Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
US6864285B1 (en) | 1999-07-07 | 2005-03-08 | Innovet Italia S.R.L. | Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the CB2 cannabinoid receptor |
ATE290858T1 (de) * | 1999-08-06 | 2005-04-15 | Innovet Italia Srl | N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin |
FR2800372B1 (fr) * | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
US6410597B1 (en) * | 2000-02-25 | 2002-06-25 | Virginia Commonwealth University | Hydroxyalkyl amide analogs of ceramide |
AU2001264930A1 (en) * | 2000-05-23 | 2001-12-03 | The Regents Of The University Of California | A novel treatment for cough |
US20020137802A1 (en) * | 2000-09-28 | 2002-09-26 | Travis Craig R. | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation |
US6541510B2 (en) * | 2000-09-28 | 2003-04-01 | Immugen Pharmaceuticals, Inc. | Antiviral methods and compounds |
US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US7025992B2 (en) * | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
GB0104268D0 (en) * | 2001-02-21 | 2001-04-11 | Unilever Plc | Antiperspirant or deodorant compositions |
TWI238068B (en) | 2001-03-06 | 2005-08-21 | Kao Corp | Composition for external application |
AU2002338329B2 (en) * | 2001-03-27 | 2006-09-07 | The Regents Of The University Of California | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
WO2002079139A1 (de) | 2001-03-29 | 2002-10-10 | Basf Aktiengesellschaft | Konjugierte ungesättigte glyceridgemische und verfahren zur ihrer herstellung |
CN1523994A (zh) * | 2001-05-23 | 2004-08-25 | 钱吉子 | 一种用于预防和/或治疗痴呆的以灵芝提取物、十八碳烯酰胺及其衍生物作为有效成分的组合物 |
ITMI20011483A1 (it) * | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
EP1406576B2 (en) * | 2001-07-18 | 2011-06-29 | Unilever PLC | Hair and/or scalp treatment compositions |
AU2002319286A1 (en) * | 2001-07-18 | 2003-03-03 | Unilever Plc | Skin treatment |
TWI250023B (en) * | 2001-10-22 | 2006-03-01 | Santen Pharmaceutical Co Ltd | Pharmaceutical composition for itch treating agent |
PL369952A1 (en) * | 2001-11-14 | 2005-05-02 | Schering Corporation | Cannabinoid receptor ligands |
EP1461027A4 (en) * | 2001-12-07 | 2005-09-07 | Univ Virginia Commonwealth | TREATMENT OF NEOPLASIA |
JPWO2003070277A1 (ja) | 2002-02-19 | 2005-06-09 | 塩野義製薬株式会社 | 抗掻痒剤 |
NZ535349A (en) | 2002-03-08 | 2007-01-26 | Signal Pharm Inc | JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular |
CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
US20030232101A1 (en) * | 2002-03-18 | 2003-12-18 | Immugen Pharmaceuticals, Inc. | Topical formulations of resorcinols and cannibinoids and methods of use |
UA79281C2 (en) * | 2002-04-03 | 2007-06-11 | Solvay Pharm Bv | Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof |
WO2004000807A1 (en) | 2002-06-19 | 2003-12-31 | Schering Corporation | Cannabinoid receptor agonists |
US20040018151A1 (en) * | 2002-07-26 | 2004-01-29 | Abood Mary E. | Use of anandamide/cannabinoid receptor/acceptor agonists in als screening and treatment methods |
MXPA05005512A (es) | 2002-11-25 | 2005-07-25 | Schering Corp | Ligandos receptores canabinoides. |
AR043633A1 (es) * | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
WO2005000829A1 (ja) | 2003-06-26 | 2005-01-06 | Takeda Pharmaceutical Company Limited | カンナビノイド受容体調節剤 |
US7193096B2 (en) | 2003-07-01 | 2007-03-20 | Loders Croklaan Usa Llc | Process for producing a conjugated di- or poly-unsaturated fatty acid of 12 to 24 carbon atoms or salt or ester thereof |
MX2007000015A (es) * | 2004-06-22 | 2007-03-07 | Schering Corp | Ligandos de receptor de canabinoide. |
AU2005314021B2 (en) * | 2004-12-09 | 2010-02-11 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
WO2008111296A1 (ja) | 2007-03-09 | 2008-09-18 | Kyoto University | 角化の亢進に起因する皮膚疾患の予防及び治療のための医薬 |
IL187247A0 (en) * | 2007-11-08 | 2008-12-29 | Hadasit Med Res Service | Novel synthetic analogs of sphingolipids |
WO2009109973A2 (en) | 2008-03-04 | 2009-09-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compounds and methods of treating obesity |
EP2174642A1 (en) * | 2008-10-10 | 2010-04-14 | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House | Use of Personal Care Composition |
US20120277296A1 (en) | 2009-07-23 | 2012-11-01 | Sophie Lotersztajn | Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease |
PL2475352T5 (pl) * | 2009-09-07 | 2019-02-28 | Epitech Group S.P.A. | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji |
CN102229527B (zh) | 2009-12-14 | 2016-05-04 | 脂质营养品有限公司 | 工艺方法 |
US10019119B2 (en) | 2010-09-09 | 2018-07-10 | 3M Innovative Properties Company | Touch sensitive device with stylus support |
EP2921167B1 (en) | 2014-03-19 | 2016-08-17 | EPITECH GROUP S.p.A. | Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine |
ES2731729T3 (es) | 2014-05-14 | 2019-11-18 | Epitech Group S P A | Uso de palmitoiletanolamida en combinación con opioides |
EP2985037B1 (en) | 2014-08-13 | 2017-06-21 | EPITECH GROUP S.p.A. | A pharmaceutical composition comprising palmitoylethanolamid and cytidine-diphosphocholine |
WO2018071679A1 (en) | 2016-10-13 | 2018-04-19 | Carnot, Llc | N-acylethanolamide derivatives and uses thereof |
PH12018000227B1 (en) | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
IT202000007831A1 (it) | 2020-04-14 | 2021-10-14 | Epitech Group S P A | Adelmidrol per l’uso nel trattamento della fibrosi polmonare |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1252865B (it) * | 1991-12-31 | 1995-06-28 | Lifegroup Spa | N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni |
IT1252866B (it) * | 1991-12-31 | 1995-06-28 | Lifegroup Spa | N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica |
IT1271623B (it) * | 1994-03-21 | 1997-06-04 | Lifegroup Spa | N-acilderivati di aminoalcoli con acidi monocarbossilici e bicarbossilici con attivita' neuroprotettiva nelle patologie neurologiche correlate ad eccitotossicita' |
-
1994
- 1994-12-14 IT ITMI942512A patent/IT1271266B/it active IP Right Grant
-
1995
- 1995-12-13 AU AU43442/96A patent/AU4344296A/en not_active Abandoned
- 1995-12-13 JP JP51826596A patent/JP4216330B2/ja not_active Expired - Fee Related
- 1995-12-13 US US08/860,356 patent/US5990170A/en not_active Expired - Lifetime
- 1995-12-13 WO PCT/EP1995/004927 patent/WO1996018391A2/en not_active Application Discontinuation
- 1995-12-13 CA CA002207850A patent/CA2207850C/en not_active Expired - Lifetime
- 1995-12-13 EP EP95942142A patent/EP0799033A1/en not_active Withdrawn
- 1995-12-14 IL IL11640095A patent/IL116400A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ITMI942512A1 (it) | 1996-06-14 |
CA2207850A1 (en) | 1996-06-20 |
WO1996018391A2 (en) | 1996-06-20 |
US5990170A (en) | 1999-11-23 |
JP4216330B2 (ja) | 2009-01-28 |
IT1271266B (it) | 1997-05-27 |
AU4344296A (en) | 1996-07-03 |
ITMI942512A0 (it) | 1994-12-14 |
JPH11500411A (ja) | 1999-01-12 |
WO1996018391A3 (en) | 1996-08-15 |
WO1996018391B1 (en) | 2001-04-05 |
EP0799033A1 (en) | 1997-10-08 |
CA2207850C (en) | 2009-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL116400A0 (en) | Therapeutic use of mono and dicarboxylic acid amides with aminoalcohols or aminoethers in the manufacture of a medicament selectively active on the cannabinoid peripheral receptor | |
IL113844A (en) | N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS | |
HUP0100042A3 (en) | Benzofuran carboxamides medicaments containing the same and their therapeutic use | |
ZA956005B (en) | Iron-containing nanoparticles their production and their use for diagnostic and therapeutic purposes | |
AP9701101A0 (en) | Skin care composition containing retinoids and liposomes | |
CA2181742A1 (en) | Reduction of skin irritation during electrotransport delivery | |
PL348349A1 (en) | Antrhranilic acid amides and the use thereof as medicaments | |
EP1173191A4 (en) | NOVEL ANTI-ANGIOGENIC PEPTIDE AGENTS, USE OF THE SAME FOR THERAPY AND DIAGNOSIS | |
GB9403250D0 (en) | Therapeutic use of myelin-associated glycoprotein (mag) | |
PL335555A1 (en) | Novel compounds - substituted benzamides and therapeutic agent | |
EP0670318A3 (de) | Acetamide mit analgetischer und neuroprotektiver Wirkung. | |
AP9300555A0 (en) | Therapeutic agent and its use | |
ZA964985B (en) | N-[1,4-diazabicyclo[2.2.2]oct-2-yl)methyl]benzamide derivatives their preparation and their applications in therapeutics | |
HU9601250D0 (en) | Biologically active silicon-compounds and their pharmaceutical and cosmetical use | |
HUP9802332A3 (en) | Fungicidal carbamoyl carboxylic acid amide derivatives, preparation and use thereof | |
WO1995025509A3 (en) | Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity | |
GR3025081T3 (en) | (s)-alpha-phenyl-2-pyridineethanamine (s)-malate and its use as a medicament | |
PH23435A (en) | Benzamide and application thereof in the therapeutic field | |
PH30808A (en) | 2-Amino-4-heteroaryl-1,-4-2dihydropyridines and their use in medicaments. | |
GB9407327D0 (en) | Biologically and therapeutically active agents against HIV-1 T | |
GB9408684D0 (en) | Biologically and therapeutically active agents | |
GB9409478D0 (en) | Biologically and therapeutically active agents | |
CA2186243A1 (en) | Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity | |
ZA963998B (en) | 3,4-Disubstituted-phenylsulphonamides and their therapeutic use | |
GB9313917D0 (en) | Respiration and oxygen therapy monitor |